Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 8, 2025
Daily News
October 8, 2025
- Japan Begins Overhaul of Patent Linkage Framework with First Notification
October 8, 2025
- Nichi-Iko to Offload AGs of Allegra and Plavix to Meiji Group
October 8, 2025
- Japan Panel OKs Basic Policy for Stockpiling Crisis-Response Medicines
October 8, 2025
- NHI-Market Price Gap Likely to Narrow Further in 2025; Will It Drop into 4% Zone?
October 8, 2025
- Turn Sakaguchi’s Nobel-Winning Research into Societal Impact: LDP Panel Chief
October 8, 2025
- Japan Sleep Society to Revise Insomnia Guidelines to Reflect Orexin Antagonists
October 8, 2025
- Kissei Grants Linzagolix Rights to Searchlight in Canada
October 8, 2025
- Enhertu Combo Filed for First-Line HER2 Breast Cancer in Japan
October 8, 2025
- Leqembi Iqlik Autoinjector Now Available in US: Eisai/Biogen
October 8, 2025
- Japan Ethical Drug Sales Edge Up 0.4% in August: Crecon
October 8, 2025
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…